A Randomized, Open-label, Multi-center, Phase I, Crossover Study to Assess the Relative Bioavailability of 2 Oral Formulations of TKI258 (CSF Capsule vs. FMI Tablet), and the Effect of Food on the Bioavailability of TKI258, in Patients With Advanced Solid Tumors.

Trial Profile

A Randomized, Open-label, Multi-center, Phase I, Crossover Study to Assess the Relative Bioavailability of 2 Oral Formulations of TKI258 (CSF Capsule vs. FMI Tablet), and the Effect of Food on the Bioavailability of TKI258, in Patients With Advanced Solid Tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Apr 2015

At a glance

  • Drugs Dovitinib (Primary)
  • Indications Solid tumours
  • Focus Pharmacokinetics
  • Most Recent Events

    • 07 Nov 2013 Planned End Date changed from 1 Jul 2013 to 1 Feb 2015 as reported by ClinicalTrials.gov.
    • 07 Jun 2013 Status changed from active, no longer recruiting to completed, based on the 49th Annual Meeting of the American Society of Clinical Oncology abstract.
    • 04 Jun 2013 Results presented at the 49th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top